1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Bispecific Antibody Therapeutics Contract Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Molecule Type/Bispecific Format
8.1.1. Full-length IgG-like Bispecifics
8.1.1.1. Market Revenue and Forecast
8.1.2. Ba Knob-into-Hole (KiH) ck
8.1.2.1. Market Revenue and Forecast
8.1.3. CrossMab
8.1.3.1. Market Revenue and Forecast
8.1.4. Dual-Variable Domain (DVD-Ig)
8.1.4.1. Market Revenue and Forecast
8.1.5. Duobody
8.1.5.1. Market Revenue and Forecast
8.1.5. Fragment-based/Non-IgG Formats
8.1.5.1. Market Revenue and Forecast
8.1.6. BiTE (Bispecific T-cell Engager)
8.1.6.1. Market Revenue and Forecast
8.1.7. DART (Dual-Affinity Re-Targeting)
8.1.7.1. Market Revenue and Forecast
8.1.8. TandAb/Nanobody
8.18.1. Market Revenue and Forecast
8.1.9. Others (scFv-based, antibody-fragment fusions)
8.1.9.1. Market Revenue and Forecast
9.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Expression System/Host Cell Line
9.1.1. Mammalian Cell Systems
9.1.1.1. Market Revenue and Forecast
9.1.2. CHO (Chinese Hamster Ovary) Cells
9.1.2.1. Market Revenue and Forecast
9.1.3. HEK293 / Human Cell Lines
9.1.3.1. Market Revenue and Forecast
9.1.4. Microbial Systems
9.1.4.1. Market Revenue and Forecast
9.1.5. E. coli Expression
9.1.5.1. Market Revenue and Forecast
9.1.6. Yeast (Pichia pastoris, Saccharomyces cerevisiae)
9.1.6.1. Market Revenue and Forecast
9.1.7. Cell-free & Novel Systems
9.1.7.1. Market Revenue and Forecast
9.1.8. Cell-free Protein Synthesis Platforms
9.1.8.1. Market Revenue and Forecast
9.1.9. Plant/Insect Expression Systems
9.1.9.1. Market Revenue and Forecast
10.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Manufacturing Stage/Service Scope
10.1.1. Process Development
10.1.1.1. Market Revenue and Forecast
10.1.2. Upstream & Downstream Process Optimization
10.1.2.1. Market Revenue and Forecast
10.1.3. Analytical & Method Development
10.1.3.1. Market Revenue and Forecast
10.1.4. Clinical Manufacturing
10.1.4.1. Market Revenue and Forecast
10.1.5. Pre-clinical & Phase I/II Production
10.1.5.1. Market Revenue and Forecast
10.1.6. GMP Scale-up Manufacturing
10.1.7.1. Market Revenue and Forecast
10.1.8. Commercial Manufacturing
10.1.8.1. Market Revenue and Forecast
10.1.9. Large-scale Batch Production
10.1.9.1. Market Revenue and Forecast
10.1.10. Fill-Finish & Final Formulation
10.1.10.1. Market Revenue and Forecast
10.1.11. Stability, QC & Release Testing
10.11.1. Market Revenue and Forecast
11.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication/Therapeutic Area
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Hematologic Malignancies (B-cell/T-cell lymphomas, leukemia)
11.1.2.1. Market Revenue and Forecast
11.1.3. Solid Tumors (lung, colorectal, breast, gastric)
11.1.3.1. Market Revenue and Forecast
11.1.4. Autoimmune & Inflammatory Diseases
11.1.4.1. Market Revenue and Forecast
11.1.5. Rheumatoid Arthritis
11.1.5.1. Market Revenue and Forecast
11.1.6. Psoriasis/Inflammatory Bowel Disease
11.1.6.1. Market Revenue and Forecast
11.1.7. Infectious Diseases
11.1.7.1. Market Revenue and Forecast
11.1.8. Viral Infections (HIV, COVID-19 candidates)
11.1.8.1. Market Revenue and Forecast
11.1.9. CNS & Others
11.1.9.1. Market Revenue and Forecast
11.1.10. Alzheimer’s Disease
11.1.10.1. Market Revenue and Forecast
11.1.11. Ophthalmic Disorders
11.1.11.1. Market Revenue and Forecast
12.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration
12.1.1. Intravenous (IV)
12.1.1.1. Market Revenue and Forecast
12.1.2. Subcutaneous (SC)
12.1.2.1. Market Revenue and Forecast
12.1.3. Intratumoral/Localized Delivery (emerging)
12.1.3.1. Market Revenue and Forecast
12.1.4. By End-User/Contracting Model
12.1.4.1. Market Revenue and Forecast
12.1.5. Pharmaceutical Companies (large biopharma outsourcing to CDMOs)
12.1.5.1. Market Revenue and Forecast
12.1.6. Biotech Companies/Emerging Players (pipeline outsourcing)
12.1.6.1. Market Revenue and Forecast
12.1.7. CDMOs/CMOs as Primary Service Providers
12.1.7.1. Market Revenue and Forecas
13.1. North America
13.1.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.1.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.1.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.1.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.1.5. Market Revenue and Forecast, by Route of Administration
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.1.6.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.1.6.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.1.6.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.1.6.5. Market Revenue and Forecast, by Route of Administration
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.1.7.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.1.7.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.1.7.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.1.7.5. Market Revenue and Forecast, by Route of Administration
13.2. Europe
13.2.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.2.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.2.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.2.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.2.5. Market Revenue and Forecast, by Route of Administration
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.2.6.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.2.6.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.2.7. Market Revenue and Forecast, by Indication/Therapeutic Area
13.2.8. Market Revenue and Forecast, by Route of Administration
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.2.9.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.2.9.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.2.10. Market Revenue and Forecast, by Indication/Therapeutic Area
13.2.11. Market Revenue and Forecast, by Route of Administration
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.2.12.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.2.12.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.2.12.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.2.13. Market Revenue and Forecast, by Route of Administration
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.2.14.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.2.14.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.2.14.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.2.15. Market Revenue and Forecast, by Route of Administration
13.3. APAC
13.3.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.3.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.3.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.3.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.3.5. Market Revenue and Forecast, by Route of Administration
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.3.6.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.3.6.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.3.6.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.3.7. Market Revenue and Forecast, by Route of Administration
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.3.8.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.3.8.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.3.8.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.3.9. Market Revenue and Forecast, by Route of Administration
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.3.10.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.3.10.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.3.10.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.3.10.5. Market Revenue and Forecast, by Route of Administration
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.3.11.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.3.11.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.3.11.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.3.11.5. Market Revenue and Forecast, by Route of Administration
13.4. MEA
13.4.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.4.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.4.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.4.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.4.5. Market Revenue and Forecast, by Route of Administration
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.4.6.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.4.6.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.4.6.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.4.7. Market Revenue and Forecast, by Route of Administration
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.4.8.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.4.8.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.4.8.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.4.9. Market Revenue and Forecast, by Route of Administration
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.4.10.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.4.10.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.4.10.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.4.10.5. Market Revenue and Forecast, by Route of Administration
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.4.11.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.4.11.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.4.11.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.4.11.5. Market Revenue and Forecast, by Route of Administration
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.5.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.5.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.5.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.5.5. Market Revenue and Forecast, by Route of Administration
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.5.6.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.5.6.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.5.6.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.5.7. Market Revenue and Forecast, by Route of Administration
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Molecule Type/Bispecific Format
13.5.8.2. Market Revenue and Forecast, by Expression System/Host Cell Line
13.5.8.3. Market Revenue and Forecast, by Manufacturing Stage/Service Scope
13.5.8.4. Market Revenue and Forecast, by Indication/Therapeutic Area
13.5.8.5. Market Revenue and Forecast, by Route of Administration
14.1. Lonza Group Ltd.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. WuXi Biologics
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Catalent, Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Fujifilm Diosynth Biotechnologies
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Boehringer Ingelheim BioXcellence™
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Thermo Fisher Scientific (Patheon)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. AbbVie Contract Manufacturing
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Abzena Plc
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. KBI Biopharma
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. AGC Biologics
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
